IRIS
IACOBELLI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.172
EU - Europa 4.861
AS - Asia 2.727
SA - Sud America 22
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 4
AF - Africa 1
Totale 12.799
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.159
CN - Cina 983
UA - Ucraina 966
SG - Singapore 897
IE - Irlanda 847
GB - Regno Unito 664
SE - Svezia 609
TR - Turchia 584
FR - Francia 565
IT - Italia 460
DE - Germania 286
FI - Finlandia 198
IN - India 194
RU - Federazione Russa 160
BE - Belgio 44
VN - Vietnam 24
CZ - Repubblica Ceca 20
BR - Brasile 19
PL - Polonia 15
EU - Europa 11
CA - Canada 10
IL - Israele 9
HK - Hong Kong 8
IR - Iran 8
JP - Giappone 5
CH - Svizzera 4
GR - Grecia 4
LT - Lituania 4
NL - Olanda 4
AU - Australia 3
ES - Italia 3
ID - Indonesia 3
RO - Romania 3
TW - Taiwan 3
AE - Emirati Arabi Uniti 2
KR - Corea 2
MX - Messico 2
PT - Portogallo 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
AT - Austria 1
AZ - Azerbaigian 1
BY - Bielorussia 1
EG - Egitto 1
IQ - Iraq 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PY - Paraguay 1
TH - Thailandia 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 12.799
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.062
Chandler 1.053
Dublin 842
Singapore 772
Southend 558
Princeton 385
Izmir 329
Nanjing 306
Santa Clara 189
Cambridge 177
Wilmington 177
Beijing 166
Boardman 134
Ann Arbor 127
Nanchang 111
Dearborn 105
Ashburn 96
Altamura 91
Woodbridge 62
Chieti 61
Hebei 53
Shenyang 50
Tianjin 46
Brussels 43
Kunming 42
Los Angeles 41
New York 39
Pescara 31
Jiaxing 29
Norwalk 26
Munich 25
Dong Ket 24
Hangzhou 23
Changsha 22
Falls Church 19
Houston 19
Kocaeli 19
Grevenbroich 18
Brno 17
Helsinki 17
Montesilvano 17
Collecorvino 16
Washington 16
San Mateo 15
Jinan 14
Kraków 14
Lanzhou 14
Orange 14
Rome 14
Leawood 13
Moscow 13
Auburn Hills 11
Augusta 10
Guangzhou 10
Changchun 9
Düsseldorf 9
Lappeenranta 9
Milan 9
Ardabil 8
Ningbo 8
Taizhou 8
Mumbai 7
Pune 7
Seattle 7
Tappahannock 7
Chicago 6
Corridonia 6
Hong Kong 6
London 6
Mcallen 6
Andover 5
Finale Ligure 5
Hefei 5
Monmouth Junction 5
Simi Valley 5
Zhengzhou 5
Anzio 4
Giulianova 4
Rio de Janeiro 4
Spoltore 4
Bangalore 3
Città Sant'Angelo 3
Francavilla al Mare 3
Fuzhou 3
Keputih 3
Madrid 3
Napoli 3
Ottawa 3
Perugia 3
Pusiano 3
Redwood City 3
Romola 3
Shanghai 3
Shijiazhuang 3
Taipei 3
Toronto 3
Baotou 2
Castellamonte 2
Cattolica 2
Cepagatti 2
Totale 7.817
Salva come PNG Salva come JPEG
Nome #
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 125
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma 120
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 119
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 111
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma 108
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 107
New Targets for Therapy in Pancreatic Cancer 107
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer 105
A comparative study of the antiinflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds 103
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 102
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 100
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 100
An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. 99
Prognostic relevance of LGALS3BP in human colorectal carcinoma 99
ERBB3 BINDING ANTIBODY 97
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 97
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates 97
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 95
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs) 95
Overexpression of PY1289-HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants 95
90K (Mac-2 BP) in human milk 93
Surgical treatment of adrenal metastases from non small cell lung cancer 93
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma 92
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 91
DNA ploidy and S-phase fraction in pulmonary carcinoids. 91
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 90
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 90
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 89
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 89
Tyrosine kinase inhibitors 89
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 89
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 88
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 88
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 88
Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. 87
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 86
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 86
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 86
Role of 90K protein in asthma and TH2-type cytokine expression. 85
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 85
Analisi dello stato mutazionale di K-RAS: un nuovo strumento per la selezione dei pazienti candidati a terapia con anticorpi anti-EGFR 85
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. 85
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 84
Unknown primary tumors 84
Novel inhibitors of pvhl-elongin c binding 84
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 82
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 82
Axillary Lymph Node Nanometastases are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients 81
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 81
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 81
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 81
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 80
Increased levels of soluble P-selectin in hypercholesterolemic patients 79
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 79
Tumor-derived microvesicles: The metastasomes. 79
Prognostic value of 90K protein in HIV infection 78
Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. 78
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 78
DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. 77
Inhibition of the Phosphatidylinositol 3-kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects. 77
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 77
Elevated Plasma Levels of 90K (Mac-2 BP) Immunostimulatory Glycoprotein in HIV-1-Infected Children 76
Prognostic value of a novel circulating serum 90K antigen in breast cancer 76
Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. 76
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 75
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 75
Immunological effects of alternative weekly interferon–alpha–2b and low dose interleukin–2 in patients with cancer 75
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 74
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 74
Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIA-IIIB non-small-cell lung cancer: a pilot study. 74
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 73
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. 73
Differential effect on TCR: CD3 stimulation of a 90-kD glycoprotein (gp90/Mac-2BP), a member of the scavenger receptor cysteine-rich domain protein family 72
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. 72
Combinations of biological response modifiers: rationale and clinical responses. 72
Lipoprotein 90K in human immunodeficiency virus-infected patients: a further serologic marker of progression. 72
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 72
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer 72
[Hairy cell leukemia: prognosis and treatment] 71
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 71
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 71
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer 71
null 70
Novel P53 mutations detected by FAMA in colorectal cancers. 70
The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. 70
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 70
Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells. 70
Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer. 70
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 69
Neoadjuvant Chemotherapy for Surgically Staged IIIA N2 Non-Small Cell Lung Cancer (NSCLC) in the Elderly 68
Phospholipase Cgamma1 is required for metastasis development and progression 68
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 68
Combined therapy in pancreatic cancer 67
Flavonoids inhibit melanoma lung metastasis by impairing tumor cells endothelium interactions. 67
A Stochastic Model for the HIV/AIDS Dynamic Evolution 67
Tumor-associated antigen 90K activates myelomonocytic cell line THP-1. 67
Tumor-associated antigen 90K activates myelomonocytic cell line THP-1 66
Immunohistochemical and serological 90K/Mac-2BP detection in hepatocellular carcinoma patients: different behaviour of two monoclonal antibodies 65
HCV genotype and serum 90K levels: host and virus related factors predict response to a-ifn therapy 64
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 64
Totale 8.305
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.895
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.895
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.112 0 0 0 0 0 105 257 226 95 182 236 11
2020/20211.180 185 9 196 10 104 229 36 15 59 194 82 61
2021/2022739 11 12 5 137 90 16 15 52 65 14 93 229
2022/20232.806 210 288 173 356 315 597 159 220 329 25 73 61
2023/20241.213 109 37 99 58 67 356 261 39 14 23 16 134
2024/20251.806 200 751 610 90 64 91 0 0 0 0 0 0
Totale 13.187